Pub. Date : 2018 Mar 2
PMID : 29568367
2 Functional Relationships(s)Download |
Sentence | Compound Name | Protein Name | Organism |
| 1 | Asciminib (previously ABL001), which binds the myristate-binding pocket of the Bcr-Abl kinase domain, is in phase I clinical trials as monotherapy and in combination with imatinib, nilotinib and dasatinib for the treatment of patients with refractory CML or Ph+ ALL. | asciminib | BCR activator of RhoGEF and GTPase | Homo sapiens |
| 2 | In K562 asciminib-resistant cells, ABCG2 expression increased prior to BCR-ABL1 overexpression and remained high (up to 7.6-fold greater levels in resistant vs control cells, p < 0.001). | asciminib | BCR activator of RhoGEF and GTPase | Homo sapiens |